Methyl Yellow

Methyl Yellow

SCHEMBL239712

CN(C)c1ccc(N=Nc2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 1.00
MAPK1 P28482 4/20 1.00
TSHR P16473 4/20 1.00
TDP1 Q9NUW8 3/20 1.00
HSD17B10 Q99714 3/20 1.00
KMT2A Q03164 7/20 0.66
RAB9A P51151 7/20 0.66
NPC1 O15118 6/20 0.66
MEN1 O00255 5/20 0.66
NSD2 O96028 1/20 0.66
CASP3 P42574 1/20 0.66
SENP8 Q96LD8 1/20 0.66
SENP7 Q9BQF6 1/20 0.66
SENP6 Q9GZR1 1/20 0.66
ALPL P05186 2/20 0.63
ALPG P10696 2/20 0.63
ALPI P09923 1/20 0.63
POLB P06746 2/20 0.62
MAOA P21397 1/20 0.61
MAOB P27338 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10909165 1.00 ALDH1A1 (1.00) ALDH1A1MAPK1TSHRTDP1HSD17B10
SCHEMBL8982830 1.00 ALDH1A1 (1.00) ALDH1A1MAPK1TSHRTDP1HSD17B10
SCHEMBL8982833 1.00 ALDH1A1 (1.00) ALDH1A1MAPK1TSHRTDP1HSD17B10
Dimethyl Yellow SCHEMBL187589 1.00 ALDH1A1 (1.00) ALDH1A1MAPK1TSHRTDP1HSD17B10
SCHEMBL8982839 1.00 ALDH1A1 (1.00) ALDH1A1MAPK1TSHRTDP1HSD17B10
Dimethyl Yellow SCHEMBL6240921 0.98 ALDH1A1 (0.95) ALDH1A1MAPK1TSHRTDP1HSD17B10
Methyl Yellow SCHEMBL6240923 0.98 ALDH1A1 (0.95) ALDH1A1MAPK1TSHRTDP1HSD17B10
Methyl Yellow SCHEMBL28233507 0.98 ALDH1A1 (0.95) ALDH1A1MAPK1TSHRTDP1HSD17B10
SCHEMBL9207409 0.94 ALDH1A1 (0.88) ALDH1A1MAPK1TSHRTDP1HSD17B10
Methyl Yellow SCHEMBL28067007 0.94 ALDH1A1 (0.88) ALDH1A1MAPK1TSHRTDP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113721354-B Zoom lens and imaging device FUJIFILM CORP. (JP) 2026-05-26 CN claimed
US-12582675-B2 Methods for treatment of cancers harboring an H3K27M mutation THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2026-03-24 US claimed
US-12492243-B2 DNA antibody constructs for use against Pseudomonas aeruginosa THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2025-12-09 US claimed
EP-4622991-A2 SYNTHESIS OF A CYCLIC PEPTIDE Janssen Pharmaceutica NV (BE) 2025-10-01 EP claimed
EP-3703150-B1 WASHER FOR SECONDARY BATTERY, SECONDARY BATTERY INCLUDING SAME, AND METHOD FOR MANUFACTURING WASHER FOR SECONDARY BATTERY LG ENERGY SOLUTION LTD (KR) 2025-08-20 EP claimed
CN-119937660-A Fully-autonomous pressure dynamic balance adjusting method of double-branch cold air propulsion system 北京控制工程研究所 2025-05-06 CN claimed
US-20250011401-A1 OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS WISTAR INST (US) 2025-01-09 US claimed
CN-118987259-A Preparation method and application of antibacterial adhesion-resistant colorectal cancer microenvironment-responsive nano-drug 天津理工大学 2024-11-22 CN claimed
US-20240383170-A1 FLEXIBLE AND SMART WOOD WITH RESPONSIVE FUNCTION, PREPARATION METHOD THEREOF AND ACTUATOR NANJING FORESTRY UNIVERSITY (CN) 2024-11-21 US claimed
US-20240376179-A1 DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS WISTAR INST (US) 2024-11-14 US claimed
US-6172261-B1 BIOSYNTHESIS USING CHAIN EXTENSION ORIDIGM CORPORATION 2001-01-09 US claimed
EP-1001927-A2 NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS ORIDIGM CORPORATION (US) 2000-05-24 EP claimed
WO-1999063333-A1 SURFACE REGENERATION OF BIOSENSORS BIACORE AB (SE) 1999-12-09 WO claimed
WO-1999003823-A2 NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS ORIDIGM CORPORATION (US) 1999-01-28 WO claimed
US-5371122-A Resolution, colorant dispersed without aggregation MITSUBOSHI BELTING LTD. (JP) 1994-12-06 US claimed
US-4904569-A Method of forming pattern and projection aligner for carrying out the same HITACHI, LTD. (JP) 1990-02-27 US claimed
US-4812532-A GLASS OR SILICA GEL SUPPORT, ANALYZING AMINES BIO-AFFINITY SYSTEMS, INC. (US) 1989-03-14 US claimed
US-4812362-A POLYMERIC COATING ON GLASS OR SILICA GEL, CHROMATOGRAPHY BIO-AFFINITY SYSTEMS, INC. (US) 1989-03-14 US claimed
WO-1989001406-A1 SOLID PHASE N-HYDROXYSUCCINIMIDE REAGENTS AND USE OF SAME BIO-AFFINITY SYSTEMS, INC. (US) 1989-02-23 WO claimed
US-3960751-A LIQUID CRYSTAL MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JA) 1976-06-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12582675-B2 Methods for treatment of cancers harboring an H3K27M mutation H1-2, CARM1, H1-3 ALDH1A1 4096/4885MAPK1 3173/4885TSHR 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.